Drug Trial Radar · NCT07163845
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,354
Actual
Start
Sep 22, 2025
Primary completion
Jul 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Valneva Austria GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Butantan Foundation; Coalition for Epidemic Preparedness Innovations
- First posted
- Sep 9, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a cross-sectional serosurvey using household cluster sampling conducted before the VLA1553 pilot vaccination strategy will be implemented in about 10 municipalities in Brazil.
Conditions
- Chikungunya Virus Infection
Interventions
Live-attenuated CHIKV vaccine VLA1553Biological
Non-interventional study: VLA1553 is used in the pilot vaccination strategy which is carried out after this observational study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To prospectively evaluate the association between vaccination uptake and previous CHIKV exposure (pre-existing immunity to CHIKV infection) after implementing a pilot vaccination in the age-group approved per label.Time frame: on Day 1
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Universidade Federal Do Ceará
Fortaleza, Ceará, Brazil
Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras
Belo Horizonte, Minas Gerais, Brazil
Fundação Faculdade Regional De Medicina De São José Do Rio Preto
São Pedro, São Paulo, Brazil
Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus
Laranjeiras, Sergipe, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.